EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation

Bianca Raffaelli iD, Thien Phu Do iD, Håkan Ashina iD, Josefin Snellman, Tina Maio-Twofoot, Messoud Ashina

Cephalalgia · 2024

DOI: 10.1177/03331024241259489 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, 2024. Verfasst von Bianca Raffaelli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Sildenafil Citrate, Cross-Over Studies, Receptors, Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lundbeck Foundation, Deutsche Forschungsgemeinschaft, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The cAMP and cGMP pathways are implicated in the initiation of migraine attacks, but their interactions remain unclear. Calcitonin gene-related peptide (CGRP) triggers migraine attacks via cAMP, whereas the phosphodiesterase-5 inhibitor sildenafil induces migraine attacks via cGMP. Our objective was to investigate whether sildenafil could induce migraine attacks in individuals with migraine pre-treated with the CGRP-receptor antibody erenumab.

Methods

In this randomized, double-blind, placebo-controlled, cross-over study, adults with migraine without aura received a single subcutaneous injection of 140 mg erenumab on day 1. They were then randomized to receive sildenafil 100 mg or placebo on two experimental days, each separated by at least one week, between days 8 and 21. The primary endpoint was the difference in the incidence of migraine attacks between sildenafil and placebo during the 12-h observation period after administration.

Results

In total, 16 participants completed the study. Ten participants (63%) experienced a migraine attack within 12 h after sildenafil administration compared to three (19%) after placebo ( p = 0.016). The median headache intensity was higher after sildenafil than after placebo (area under the curve (AUC) for the 12-h observation period, p = 0.026). Furthermore, sildenafil induced a significant decrease in mean arterial blood pressure (AUC, p = 0.026) and a simultaneous increase in heart rate (AUC, p < 0.001) during the first hour after administration compared to placebo.

Conclusion

These findings provide evidence that migraine induction via the cGMP pathway can occur even under CGRP receptor blockade.

Trial registration

ClinicalTrials.gov: Identifier NCT05889455.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sildenafil CitrateCross-Over StudiesReceptors, Calcitonin Gene-Related PeptideMigraine DisordersCyclic GMPHumansAdultMaleDouble-Blind MethodFemaleMiddle AgedAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsPhosphodiesterase 5 InhibitorsYoung Adult

Stichwörter der Autor:innen

CGRPPDE-5cGMPhuman modelsmigrainetrigeminovascular system

Substanzen

Sildenafil CitrateReceptors, Calcitonin Gene-Related PeptideCyclic GMPerenumabAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsPhosphodiesterase 5 Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Clinician Scientist Program, Berlin Institute of Health at Charité (BIH), Berlin, Germany.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Translational Research Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Novartis Pharma AG, Basel, Switzerland.

ORCID-Profile: Bianca Raffaelli, Thien Phu Do, Håkan Ashina

Förderung

  • Lundbeck Foundation
  • Deutsche Forschungsgemeinschaft
  • Novartis

Zitieren

APA

Raffaelli, B., Do, T. P., Ashina, H., Snellman, J., Maio-Twofoot, T., & Ashina, M. (2024). Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation. Cephalalgia. https://doi.org/10.1177/03331024241259489

Vancouver

Raffaelli B, Do TP, Ashina H, Snellman J, Maio-Twofoot T, Ashina M. Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation. Cephalalgia. 2024. doi:10.1177/03331024241259489

BibTeX
@article{Raffaelli2024,
  author = {Raffaelli, Bianca and Do, Thien Phu and Ashina, Håkan and Snellman, Josefin and Maio-Twofoot, Tina and Ashina, Messoud},
  title = {Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation},
  journal = {Cephalalgia},
  year = {2024},
  doi = {10.1177/03331024241259489}
}
Kostenlos starten →